Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.73 |
| ▸ | FAAH | O00519 | 3/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17652547 | 0.91 | HIF1A (0.81) | HIF1AFAAHHDAC3HDAC1HDAC2 | |
| SCHEMBL17652557 | 0.88 | HDAC6 (0.74) | HIF1AFAAHHDAC3HDAC1HDAC2 | |
| SCHEMBL17510986 | 0.87 | HIF1A (0.75) | HIF1AFAAHHDAC3HDAC1HDAC2 | |
| SCHEMBL68906 | 0.87 | HIF1A (0.70) | HIF1AFAAHHDAC3HDAC1HDAC2 | |
| SCHEMBL17652545 | 0.87 | HIF1A (0.67) | HIF1AFAAHHDAC3HDAC1HDAC2 | |
| SCHEMBL17087759 | 0.87 | HIF1A (0.67) | HIF1AFAAHHDAC3HDAC1HDAC2 | |
| SCHEMBL26079027 | 0.87 | HIF1A (0.67) | HIF1AFAAHHDAC3HDAC1HDAC2 | |
| SCHEMBL12349834 | 0.86 | TP53 (0.78) | HIF1AFAAHHDAC3HDAC1HDAC2 | |
| SCHEMBL17511094 | 0.86 | HIF1A (0.73) | HIF1AFAAHHDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL17079188 | 0.85 | HDAC3 (0.65) | HIF1AFAAHHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855249-B2 | Isoxazole compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-9855249-B2 | Isoxazole compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-9790219-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790219-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790219-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-3116501-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20170001993-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170001993-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170001993-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20160128984-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2016-05-12 | — | — | US | disclosed |
| US-20160128984-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2016-05-12 | — | — | US | disclosed |
| US-20160128984-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2016-05-12 | — | — | US | disclosed |
| WO-2016054560-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054560-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2015138909-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015138909-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001993-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, KEAP1 | HIF1A 2336/4885FAAH 1749/4885HDAC3 1519/4885 |
| US-20160128984-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | HIF1A 869/4885FAAH 2514/4885HDAC3 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.